Please assess the completion status of the following clinical trial:

Trial Title: Inactivated Influenza Vaccine Effectiveness in Tropical Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female child at least 6 months of age and no older than 10 years of age (has not yet reached 11 years of age) at the enrollment visit.~* A child whose parent or guardian's primary residence, at the time of study vaccinations, is a village compound selected to receive TIV or IPV.~* Subject's parent or legal guardian is willing to provide written informed consent prior to the subject's first study vaccination.~Exclusion Criteria:~* Hypersensitivity to the active substance or any component in either TIV (which includes egg protein) or IPV. (Please see information on composition of vaccines.)~* Hypersensitivity after previous administration of any influenza or polio vaccine.~* Acute severe febrile illness. (Administration of TIV or IPV should be postponed until after recovery. Minor illnesses, such as mild upper respiratory infection, with or without low grade fever, are not reason for postponing vaccination. Acute severe febrile illness is only a temporary exclusion.)~* Any condition that, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- TIV (Type: EXPERIMENTAL): Children living in villages randomized to influenza vaccine
- IPV (Type: EXPERIMENTAL): Children living in villages randomized to polio vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).